Please use this identifier to cite or link to this item:
Title: Advances in the systemic therapy of malignant pleural mesothelioma.
Authors: Fennell, DA
Gaudino, G
O'Byrne, KJ
Mutti, L
van Meerbeeck J
First Published: Mar-2008
Citation: NAT CLIN PRACT ONCOL, 2008, 5 (3), pp. 136-147
Abstract: Malignant pleural mesothelioma is an aggressive thoracic malignancy associated with exposure to asbestos, and its incidence is anticipated to increase during the first half of this century. Chemotherapy is the mainstay of treatment, yet sufficiently robust evidence to substantiate the current standard of care has emerged only in the past 5 years. This Review summarizes the evidence supporting the clinical activity of chemotherapy, discusses the use of end points for its assessment and examines the influence of clinical and biochemical prognostic factors on the natural history of malignant pleural mesothelioma. Early-phase clinical trials of second-line and novel agents are emerging from an increased understanding of mesothelioma cell biology. Coupled with high-quality translational research, such developments have real potential to improve the outlook of patients at a time of increasing incidence.
DOI Link: 10.1038/ncponc1039
eISSN: 1743-4262
Type: Journal Article
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
There are no files associated with this item.

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.